These effects are confirmed by multiple experimental loss-of-function myostatin mutations or deletions in animal models which consistently show that attenuation of myostatin leads to an increase in the size and number of skeletal muscle fibers and muscle mass [69,70], opposite to the observations in CKD and ESRD. Here, MSTN is linked to chronic kidney disease.